Hub will focus on supporting global use of new treatments that effectively treated drug-resistant TB in 98% of Filipino participants MANILA (25 March 2024)—TB Alliance’s new Peer-to-Peer Learning for...
TB Alliance Updates
Search
Refine the list with filters
Search helpList
Showing 1 - 9 of 9 results
New Drug-Resistant TB Treatments Reach Patients in Pakistan as Association for Social Development Accelerates Pilot Implementation
Preliminary results show increased cure rates for hard-to-treat TB infections; leads to update in Pakistan’s treatment guidelines ISLAMABAD and PRETORIA (9 November 2023)—The Association for Social...
New WHO Global TB Report Shows Recovery in Effort to Combat TB, but Stronger Investments are Needed to Help Reach UN Goals
Statement from Mel Spigelman, M.D., President and Chief Executive Officer, TB Alliance “We are heartened to see that progress against tuberculosis (TB) has started to rebound after several years of...
UN Commitment on Tuberculosis Needs Leadership to Match Ambition
Statement from Mel Spigelman, MD, President and CEO of TB Alliance September 22, 2023 TB Alliance wholeheartedly supports the commitment made today at the United Nations High-Level Meeting on...
Ukraine + 2 more
Kyrgyzstan, Ukraine, and Uzbekistan Update National Guidelines for Drug-Resistant TB Treatment to Advance National Rollout of Three-Drug, Six-Month Regimen
Interim results of operational research in LIFT-TB countries support decision to roll out improved treatment PRETORIA (September 19, 2023) — Kyrgyzstan, Ukraine, and Uzbekistan — participants in the...
TB Alliance Statement on United Nations Multi-Stakeholder Hearing on Tuberculosis | Statement from Mel Spigelman, MD, President and CEO, TB Alliance
NEW YORK CITY, 8 MAY 2023: TB Alliance urges world leaders to unleash the power of science and the best qualities of humanity to end TB. In spite of all the headwinds that COVID-19 has presented,...
Innovation Deficit: Funds for Neglected Diseases like TB are Falling Short
NEW YORK (January 31, 2023)—The 2022 G-FINDER Report, released today, reveals that for the year 2021, global funding for the development of critical new health technologies to overcome the world’s...
Price reduction paves the way for expanded access to highly effective multidrug-resistant tuberculosis treatment
19 December 2022: Viatris, a global healthcare company, MedAccess, and TB Alliance have announced a new agreement to reduce the price of pretomanid, a drug used to treat multidrug-resistant...
TB Alliance Statement on New World Health Organization Rapid Communication on Key Changes to the Treatment of Drug-Resistant Tuberculosis
New Guidelines Have Potential to Transform the TB Treatment Landscape with Six-Month Standard PRETORIA (3 May 2022)---TB Alliance applauds today's rapid communication regarding new guidelines for...